Following a surge in demand for its weight-loss drug Wegovy and diabetes medication Ozempic, Danish pharmaceutical company Novo Nordisk (NYSE:NVO) has revised its full-year sales and operating profit ...

Novo Nordisk , whose global profile has risen along with demand for its Wegovy weight-loss drug, is bolstering operations in ...

One of the downsides of treatments such as Ozempic or Mounjaro is that even though patients wind up losing weight, they also tend to shed muscle mass. Losing too much muscle mass can be a health risk ...

Novo Nordisk’s stock declined 12% in the past month. Wegovy's sales growth stays under pressure. Read why I'm neutral on NVO ...

Senator Elizabeth Warren told the Federal Trade Commission that the acquisition of contract manufacturer Catalent could ...

Novo Nordisk and Viatris have agreed to resolve a patent dispute related to Novo's blockbuster weight-loss drugs Ozempic and ...

U.S. Sen. Elizabeth Warren has asked the Federal Trade Commission “closely scrutinize” a $16.5 billion deal in which Novo ...

WeightWatchers said on Tuesday it would offer a compounded version of Novo Nordisk's popular obesity drug Wegovy as part of ...

Danish drug maker Novo Nordisk has struck partnerships with 10 Indian artificial intelligence (AI) startups to streamline its ...

Senate Democrat Elizabeth Warren urges the Federal Trade Commission to closely scrutinize a proposed merger between Novo Nordisk and contract development and manufacturing organization Catalent, ...

The general mood among these heavyweight investors is divided, with 45% leaning bullish and 50% bearish. Among these notable ...

WeightWatchers said on Tuesday it would offer compounded form of Novo Nordisk's popular obesity drug Wegovy as part of its ...